$1.32
0.0251.92%
마지막 업데이트: Oct 20, 3:21 PM
$1.28
-0.02-1.54%
Benzinga
Benzinga
Benzinga
화요일, 10월 20
Benzinga
© 2026 Benzinga | All Rights Reserved
Allogene Therapeutics (ALLO) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.15 | $-0.18 | $-0.23 | $-0.23 |
| Actual | $-0.13 | $-0.18 | $-0.17 | $-0.19 |
| Surprise | +13.3% | 0.00% | +26.1% | +17.4% |
| Revenue | ||||
| Estimate | $2220 | $1820 | $2000 | $1820 |
| Actual | $4.6M | $0 | $0 | $0 |
| Surprise | +208909.0% | -100.0% | -100.0% | -100.0% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.14 | $-0.14 | $-0.14 | $-0.14 |
| Revenue | ||||
| Consensus | $2000 | $2000 | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $-0.13 | $-0.15 | 13.3 % |
| Q1 | May 13, 2026 | $-0.18 | $-0.18 | 0.00 % |
| Q4 | Mar 12, 2026 | $-0.17 | $-0.23 | 26.1 % |
| Q3 | Nov 6, 2025 | $-0.19 | $-0.23 | 17.4 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 12, 2026 | $4.64M | $2.22K | 208909.0 % |
| Q1 | May 13, 2026 | $0 | $1.82K | -100.0 % |
| Q4 | Mar 12, 2026 | $0 | $2.00K | -100.0 % |
| Q3 | Nov 6, 2025 | $0 | $1.82K | -100.0 % |